中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 850-855

Clinical features of patients with malignant tumor-related pyogenic liver abscess

DOI: 10.3969/j.issn.1001-5256.2023.04.016

  • Department of Infectious Diseases, The Second Affiliated of Air Force Medical University, Xi'an 710038, China

Research funding:

Shaanxi Provincial Key Research and Development Program (2022SF-186)

More Information
  • Corresponding author: WANG Chunfu, wcf402@163.com (ORCID: 0000-0003-0879-3933)
  • Received Date: 2022-09-08
  • Accepted Date: 2022-10-17
  • Published Date: 2023-04-20
    Abstract
  •   Objective  To investigate the clinical features of malignant tumor-related pyogenic liver abscess (PLA), and to provide a basis for early judgment of disease progression and timely and effective treatment.  Methods  A retrospective analysis was performed for the clinical data of 371 patients with PLA who were admitted to the Second Affiliated of Air Force Medical University, from March 2005 to July 2018, among whom 34 patients with malignant tumor-related PLA were enrolled as tumor group, and after matching for time and at a ratio of 1∶2, 70 patients without malignant tumor-related PLA were enrolled as non-tumor group. Clinical features were compared between the two groups. The group t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups.  Results  In the tumor group, there were 22 patients with hepatobiliary tumor (64.7%), 7 patients with gastrointestinal tumor (20.6%), and 5 patients with non-gastrointestinal tumor (14.7%). Compared with the non-tumor group, the tumor group had a significantly higher proportion of patients with a history of abdominal surgery (44.1% vs 7.1%, χ2=20.142, P < 0.05), liver cirrhosis (26.5% vs 7.1%, χ2=7.338, P < 0.05), or an Acute Physiology and Chronic Health Evaluation Ⅱ score of > 16 (44.1% vs 15.7%, χ2=9.846, P=0.002). Compared with the non-tumor group in terms of laboratory examination, the tumor group had a significantly lower level of albumin [(27.2±5.2) g/L vs (30.8±2.6) g/L, t=-3.131, P=0.002] and a significantly higher level of total bilirubin [54(13~313) μmol/L vs 33(7~96) μmol/L, U=1 816.0, P < 0.001]. Escherichia coli was the main pathogen in the tumor group (23.5%), while Klebsiella pneumonia was the main pathogen in the non-tumor group (23.5%), and compared with the non-tumor group, the tumor group had a significantly higher proportion of patients infected with more than two types of bacteria (11.8% vs 2.8%). Radiological examination showed that the tumor group had a significantly higher proportion of patients with multiple abscesses than the non-tumor group (47.1% vs 24.3%, χ2=5.479, P=0.019). Compared with the non-tumor group, the tumor group had a significantly longer mean length of hospital stay (U=1 728.5, P < 0.001) and a significantly higher treatment failure rate (P=0.005).  Conclusion  Patients with malignant tumor-related PLA often have hepatobiliary tumor, with Escherichia coli as the main pathogen. Abscesses at multiple sites are common, and patients tend to have a poor prognosis. Appropriate antibiotics combined with percutaneous drainage should be used in clinical practice, and for the high-risk population, the threshold for surgical intervention can be lowered to reduce mortality.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    RAHIMIAN J, WILSON T, ORAM V, et al. Pyogenic liver abscess: recent trends in etiology and mortality[J]. Clin Infect Dis, 2004, 39(11): 1654-1659. DOI: 10.1086/425616.
    [2]
    SEETO RK, ROCKEY DC. Pyogenic liver abscess. Changes in etiology, management, and outcome[J]. Medicine (Baltimore), 1996, 75(2): 99-113. DOI: 10.1097/00005792-199603000-00006.
    [3]
    YEH TS, JAN YY, JENG LB, et al. Pyogenic liver abscesses in patients with malignant disease: a report of 52 cases treated at a single institution[J]. Arch Surg, 1998, 133(3): 242-245. DOI: 10.1001/archsurg.133.3.242.
    [4]
    MAVILIA MG, MOLINA M, WU GY. The evolving nature of hepatic abscess: A review[J]. J Clin Transl Hepatol, 2016, 4(2): 158-168. DOI: 10.14218/JCTH.2016.00004.
    [5]
    XIAO J, XIN XJ. Analysis of clinical characteristics of pyogenic liver abscess patients with diabetes mellitus[J]. China Med Herald, 2021, 18(14): 128-131. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202114032.htm

    肖娟, 辛小娟. 细菌性肝脓肿合并糖尿病患者的临床特征分析[J]. 中国医药导报, 2021, 18(14): 128-131. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202114032.htm
    [6]
    LV WF, LU D, HE YS, et al. Liver abscess formation following transarterial chemoembolization: Clinical features, risk factors, bacteria spectrum, and percutaneous catheter drainage[J]. Medicine (Baltimore), 2016, 95(17): e3503. DOI: 10.1097/MD.0000000000003503.
    [7]
    de BAÈRE T, ROCHE A, AMENABAR JM, et al. Liver abscess formation after local treatment of liver tumors[J]. Hepatology, 1996, 23(6): 1436-1440. DOI: 10.1002/hep.510230620.
    [8]
    FACCIORUSSO A, DI MASO M, MUSCATIELLO N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis[J]. Dig Liver Dis, 2016, 48(6): 571-577. DOI: 10.1016/j.dld.2016.02.005.
    [9]
    LARDIÈRE-DEGUELTE S, RAGOT E, AMROUN K, et al. Hepatic abscess: Diagnosis and management[J]. J Visc Surg, 2015, 152(4): 231-243. DOI: 10.1016/j.jviscsurg.2015.01.013.
    [10]
    MUKTHINUTHALAPATI V, ATTAR BM, PARRA-RODRIGUEZ L, et al. Risk factors, management, and outcomes of pyogenic liver abscess in a us safety net hospital[J]. Dig Dis Sci, 2020, 65(5): 1529-1538. DOI: 10.1007/s10620-019-05851-9.
    [11]
    YU SL, WENG XH. Antimicrobial therapy in adult patients with bacterial liver abscess[J]. J Prac Hepatol, 2015, 18(4): 337-339. DOI: 10.3969/j.issn.1672-5069.2015.04.001.

    虞胜镭, 翁心华. 成人细菌性肝脓肿的抗感染治疗要点与进展[J]. 实用肝脏病杂志, 2015, 18(4): 337-339. DOI: 10.3969/j.issn.1672-5069.2015.04.001.
    [12]
    ROSSI G, NGUYEN Y, LAFONT E, et al. Large retrospective study analysing predictive factors of primary treatment failure, recurrence and death in pyogenic liver abscesses[J]. Infection, 2022, 50(5): 1205-1215. DOI: 10.1007/s15010-022-01793-z.
    [13]
    LI W, WU C, QIN M, et al. The aura of malignant tumor: Clinical analysis of malignant tumor-related pyogenic liver abscess[J]. Medicine (Baltimore), 2020, 99(9): e19282. DOI: 10.1097/MD.0000000000019282.
    [14]
    WANG Y, WANG Y, LIU K, et al. Pyogenic liver abscess as initial presentation of colon cancer: a case report[J]. Gastroenterol Nurs, 2020, 43(6): 470-473. DOI: 10.1097/SGA.0000000000000558.
    [15]
    CHONG VH, LIM KS. Pyogenic liver abscess as the first manifestation of hepatobiliary malignancy[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(5): 547-550.
    [16]
    DESALEGN H, TESFAYE A, SHUME P. Pyogenic liver abscess presenting as an initial manifestation of underlying hepatocellular cancer: A case report in ethiopia[J]. Ethiop J Health Sci, 2022, 32(3): 665-668. DOI: 10.4314/ejhs.v32i3.24.
    [17]
    ZHANG CL, GUO JJ, JIA TY, et al. Clinical and pathogenic characteristics in 75 patients with pyogenic liver abscess[J]. Infect Dis Info, 2014, 27(3): 157-159. DOI: 1007-8134(2014)03-0157-04.
    [18]
    WANG Y, LI WK, SU JY, et al. Clinical characteristics of bacterial liver abscess and its risk factors in ICU[J]. J Clin Exp Med, 2022, 21(20): 2233-2238. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLC202220029.htm

    王芸, 李文坤, 苏珈仪, 等. 细菌性肝脓肿临床特征及其入住重症监护室危险因素分析[J]. 临床和实验医学杂志, 2022, 21(20): 2233-2238. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLC202220029.htm
    [19]
    XU J, ZHOU X, ZHENG C. The geriatric nutritional risk index independently predicts adverse outcomes in patients with pyogenic liver abscess[J]. BMC Geriatr, 2019, 19(1): 14. DOI: 10.1186/s12877-019-1030-5.
    [20]
    CHOK KS, CHEUNG TT, CHAN AC, et al. Liver resection for de novo hepatocellular carcinoma complicated by pyogenic liver abscess: A clinical challenge[J]. World J Surg, 2016, 40(2): 412-418. DOI: 10.1007/s00268-015-3239-6.
    [21]
    ZHUANG HX, HUANG WP. Analysis of pyogenic liver abscesses of biliary and cryptogenic origin[J]. Mod Med J China, 2017, 19(9): 23-26. DOI: 10.3969/j.issn.1672-9463.2017.09.007.

    庄涵虚, 黄伟平. 胆源性肝脓肿和隐源性肝脓肿临床特征分析[J]. 中国现代医药杂志, 2017, 19(9): 23-26. DOI: 10.3969/j.issn.1672-9463.2017.09.007.
    [22]
    RUIZ-HERNÁNDEZ JJ, CONDE-MARTEL A, SERRANO-FUENTES M, et al. Pyogenic liver abscesses due to Escherichia coli are still related to worse outcomes[J]. Ir J Med Sci, 2020, 189(1): 155-161. DOI: 10.1007/s11845-019-02041-4.
    [23]
    CHEN SC, TSAI SJ, CHEN CH, et al. Predictors of mortality in patients with pyogenic liver abscess[J]. Neth J Med, 2008, 66(5): 196-203.
    [24]
    YAO N, KANG W, LIAN JQ, et al. Clinical features of liver abscess versus[J]. J Clin Hepatol, 2020, 36(9): 2010-2014. DOI: 10.3969/j.issn.1001-5256.2020.09.020.

    姚娜, 康文, 连建奇, 等. 肺炎克雷伯菌肝脓肿与大肠埃希菌肝脓肿临床特点对比分析[J]. 临床肝胆病杂志, 2020, 36(9): 2010-2014. DOI: 10.3969/j.issn.1001-5256.2020.09.020.
    [25]
    TAN YM, CHUNG AY, CHOW PK, et al. An appraisal of surgical and percutaneous drainage for pyogenic liver abscesses larger than 5 cm[J]. Ann Surg, 2005, 241(3): 485-490. DOI: 10.1097/01.sla.0000154265.14006.47.
    [26]
    CHEN CH, WU SS, CHANG HC, et al. Initial presentations and final outcomes of primary pyogenic liver abscess: a cross-sectional study[J]. BMC Gastroenterol, 2014, 14: 133. DOI: 10.1186/1471-230X-14-133.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (300) PDF downloads(38) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return